Reuters logo
4 months ago
BRIEF-Cara Therapeutics announces positive top-line data from Part A of Phase 2/3 Trial of I.V. CR845 in chronic kidney disease-associated pruritus
March 28, 2017 / 11:27 AM / 4 months ago

BRIEF-Cara Therapeutics announces positive top-line data from Part A of Phase 2/3 Trial of I.V. CR845 in chronic kidney disease-associated pruritus

1 Min Read

March 28 (Reuters) - Cara Therapeutics Inc

* Cara Therapeutics announces positive top-line data from part A of phase 2/3 trial of I.V. CR845 in chronic kidney disease-associated pruritus

* Trial met primary endpoint with 68% reduction in worst itching scores versus placebo after eight-week treatment period (P<0.0019)

* Trial met secondary endpoint in quality of life domains versus placebo after eight-week treatment period

* I.V. CR845 well tolerated after eight weeks of treatment

* Plans to meet with U.S. FDA for end-of-phase 2 meeting to review results to determine optimal dose to take into part B of Phase 2/3 study Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below